NASDAQ:EVLO

Evelo Biosciences Stock Forecast, Price & News

$8.34
+1.03 (+14.09 %)
(As of 09/17/2021 04:00 PM ET)
Add
Compare
Today's Range
$7.33
$8.97
50-Day Range
$6.79
$13.90
52-Week Range
$3.82
$19.93
Volume1.00 million shs
Average Volume205,895 shs
Market Capitalization$445.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
30 days | 90 days | 365 days | Advanced Chart
Receive EVLO News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Evelo Biosciences logo

About Evelo Biosciences

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases; EDP2939 for inflammation; and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

596th out of 1,350 stocks

Pharmaceutical Preparations Industry

292nd out of 664 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions

Is Evelo Biosciences a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Evelo Biosciences stock.
View analyst ratings for Evelo Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Evelo Biosciences?

Wall Street analysts have given Evelo Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evelo Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Evelo Biosciences' next earnings date?

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Evelo Biosciences
.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) released its quarterly earnings data on Wednesday, July, 28th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.01.
View Evelo Biosciences' earnings history
.

How has Evelo Biosciences' stock been impacted by COVID-19?

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EVLO shares have increased by 90.8% and is now trading at $8.34.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EVLO?

5 Wall Street analysts have issued 1 year price objectives for Evelo Biosciences' stock. Their forecasts range from $12.00 to $38.00. On average, they anticipate Evelo Biosciences' share price to reach $21.80 in the next year. This suggests a possible upside of 161.4% from the stock's current price.
View analysts' price targets for Evelo Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Evelo Biosciences' key executives?

Evelo Biosciences' management team includes the following people:
  • Simba Gill, President, Chief Executive Officer & Director
  • Luca Scavo, Chief Financial Officer, Treasurer & Senior VP
  • Mark Bodmer, Chief Scientific Officer, President-R&D
  • Andrea Itano, Senior Vice President & Head-Research
  • Duncan McHale, Chief Medical Officer

Who are some of Evelo Biosciences' key competitors?

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Who are Evelo Biosciences' major shareholders?

Evelo Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (14.99%), Credit Suisse AG (5.80%), BlackRock Inc. (3.45%), Vanguard Group Inc. (2.77%), State Street Corp (0.92%) and Geode Capital Management LLC (0.88%). Company insiders that own Evelo Biosciences stock include David R Epstein, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends for Evelo Biosciences
.

Which institutional investors are selling Evelo Biosciences stock?

EVLO stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Marshall Wace LLP, Millennium Management LLC, JPMorgan Chase & Co., AQR Capital Management LLC, Bank of America Corp DE, Citadel Advisors LLC, and Morgan Stanley.
View insider buying and selling activity for Evelo Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Evelo Biosciences stock?

EVLO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Credit Suisse AG, Geode Capital Management LLC, Northern Trust Corp, Nuveen Asset Management LLC, and Alberta Investment Management Corp. Company insiders that have bought Evelo Biosciences stock in the last two years include David R Epstein, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Evelo Biosciences
or or view top insider-buying stocks.

How do I buy shares of Evelo Biosciences?

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $8.34.

How much money does Evelo Biosciences make?

Evelo Biosciences has a market capitalization of $445.36 million. The company earns $-93,670,000.00 in net income (profit) each year or ($2.37) on an earnings per share basis.

How many employees does Evelo Biosciences have?

Evelo Biosciences employs 2,018 workers across the globe.

What is Evelo Biosciences' official website?

The official website for Evelo Biosciences is www.evelobio.com.

Where are Evelo Biosciences' headquarters?

Evelo Biosciences is headquartered at 620 Memorial Drive Suite 500 West, Cambridge MA, 02139.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at (617) 577-0300 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.